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1. SUMMARY
Background: Cardiac Syndrome X (CSX) is characterized by the presence of typical 
chest pain, a positive exercise test result and normal coronary arteries upon angiographic 
examination. The development of this syndrome is thought to be heterogeneous, involving 
many pathogenic mechanisms. Among other mechanisms, impaired endothelial function 
may predominantly contribute to the pathogenesis of symptoms in CSX patients.
In this work we prospectively evaluated the role of endothelial function, using non-invasive 
peripheral arterial tonometry, in a cohort of patients which included healthy patients, 
patients with coronary artery disease and patients with CSX, from Italian-speaking 
Switzerland.
Methods: We examined systemic endothelial function in a cohort of 37 patients: 8 healthy 
patients, 15 patients with coronary artery disease and 14 CSX patients. The latter were 
identified from the Swiss-Italian cohort of the “Italian registry of patients with Cardiac 
Syndrome X” (“Registro italiano dei pazienti con Sindrome X”). Endothelial function was 
assessed using peripheral arterial tonometry, a validated and FDA (U.S. Food and Drug 
Administration) approved tool for the examination of systemic and coronary endothelial 
function in humans [1-5].
Results: The average values for the two main indexes measured, the “Endopat index” and 
the “Endopat index according to Bonetti”, were over the discriminatory value of 1.67 for all 
studied groups. A value of less than 1.67 indicates the presence of endothelial dysfunction. 
Statistical analysis failed to demonstrate a significant difference between studied groups (p 
value of 0.442 and 0.417 respectively). Larger differences could be extrapolated in some 
selected subgroups, but in our study, the number of patients was too small to allow 
statistical analysis of the significance of the results.
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Conclusion: Our results, based on a relatively small sample of patients with CSX, do not 
show a significant difference in endothelial function, measured by peripheral arterial 
tonometry, between patients with CSX and patients with coronary artery disease. The 
interpretation of these results, which contrast with some previous studies, is not absolute. 
The multitude of mechanisms involved in the development of this syndrome makes 
investigation of this condition, and, in particular, interpretation of results yielded from small 
cohorts, challenging. Moreover, the impact of the methodology used for the measurement 
of endothelial function, and the similar prevalence of risk factors in the two “non-healthy” 
patient groups (coronary artery disease patients and CSX patients) may have contributed 
to the neutrality of the data in our study. 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2. INTRODUCTION
2.1 Definition
The first data on patients, who would now be classified as suffering from Cardiac 
Syndrome X, were published in 1967 [6,7], although it is likely that it was Sir William Osler, 
who first described this condition, in 1892, in "The Principles and Practice of Medicine”. 
Osler described a condition defined as “hysterical angina” or “pseudo-angina”, whereby 
patients presented with typical angina, along with normal coronary arteries, demonstrated 
post-mortem [8]. 
The term “Cardiac Syndrome X” was first introduced in 1973 by Kemp [9]. Cardiac 
Syndrome X (CSX) is a type of microvascular angina. In contrast to coronary artery 
disease (CAD), which is caused by the formation of plaques that can mechanically 
counteract blood circulation, in vessels of relatively large calibre, microvascular angina is 
limited to smaller calibre arteries. Furthermore, the accompanying ischaemia is not due to 
the presence of atherosclerotic plaques. The decrease in blood flow is due to other 
mechanisms, including internal vessel wall dysfunction which leads to macro- or micro-
vascular vasoconstriction, with subsequent diminished blood flow. 
CSX is a rare disorder, characterized by: 
1) exertion angina or pseudo-angina associated symptoms 
2) electrically positive stress test results 
3) no angiographic evidence of coronary disease. 
Some authors consider the presence of other systemic diseases (cardiovascular related 
diseases and other conditions such as hypertension and diabetes mellitus) as exclusion 
criteria. However, not all studies concerning CSX take these factors into account [10]. A 
new, less restrictive, definition of  CSX, was proposed by Lanza in 2007 [11]. However, in 
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the absence of a consensus, and in the context of this work, we will define CSX as 
described above, according to the classic definition. 
2.2 Background 
The pathogenic mechanisms of CSX are probably multiple and complex, with a 
predominant role played by cardiac ischaemia, a mechanism originally proposed by 
Cannon et al. in the 1980s [12] and 1990s [13], and later supported by the work of Painting 
et al. in 2002 [14]. However, the theory that proposes ischaemia as the pathophysiological 
cause of pain in CSX is not universally accepted, or, more precisely, ischaemia as an 
essential factor in the development of CSX has not been definitively proven [15]. 
A further possible feature, which does not exclude other contributory mechanisms, is an 
increased sensitivity to cardiac pain [16]. It is also evident that, among the possible 
mechanisms responsible for cardiac ischaemia in patients without coronary artery disease, 
there is not only CSX, but there are other causes, such as coronary vasospasm 
(vasospastic angina or Prinzmetal’s angina), thrombotic phenomena with rapid 
spontaneous lysis of the thrombus, cocaine use, as well as inherited thrombophilia [17]. 
These phenomena, however, fail to account for the entire range of symptoms recorded for 
patients presenting with chest pain in the context of healthy coronary arteries [17]. 
The ischaemic origins of CSX have been attributed to microvascular abnormalities [18], 
resulting from endothelial dysfunction related disorders, autonomic nervous system 
dysfunction and occult coronary artery disease. Endothelial dysfunction appears to play a 
prominent role in the development of microvascular abnormalities, but is probably just one 
part of a multifactorial process, and it is likely that other factors such as hypertension, 
hypercholesterolaemia, diabetes mellitus and smoking may contribute. Moreover, it has 
previously been observed in other studies, that patients with endothelial dysfunction have 
an increased risk of adverse cardiovascular events during follow-up [19,20], further 
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supporting the potential involvement of the risk factors mentioned above in disease 
development. 
Much is known about coronary endothelial function in the context of CSX [21-23]. 
However, the amount of data on systemic endothelial function in the context of this rare 
disease is minimal. Nevertheless we have strong evidence suggesting a correlation 
between coronary endothelial function and systemic endothelial function in various 
pathological processes [24,25]. Considering that the measurement of coronary endothelial 
function is complex and generally invasive, a method which would allow reliable function 
assessment, non-invasively, would be valuable. Such a method could also address 
questions such as, in the context of cardiac endothelial dysfunction being related to 
systemic endothelial dysfunction, establishing whether the reverse is also true, i.e. if 
systemic endothelial dysfunction is also associated with coronary endothelial dysfunction. 
A positive answer to this question could confirm the role of coronary endothelial 
dysfunction in the pathophysiology of CSX. In addition, a non-invasive and easy to use 
technique would be very useful for the identification of patients with endothelial 
dysfunction, since, as previously mentioned, these patients have a higher risk of 
presenting adverse cardiovascular events. In parallel, we may be able to more easily 
evaluate the efficacy of potential pharmacological interventions for treatment of this rare 
disease. Identification of an independent target (i. e. endothelial dysfunction), moreover, 
would be very important to restrict the indications for therapeutic (pharmacological and 
non-pharmacological) actions, and would also be of great benefit from an economic point 
of view, given the costs induced by current therapies, especially in cases where therapies 
are utilised in patients presenting with chest pain without underlying obstructive coronary 
artery disease [26]. 
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2.3 Epidemiology
According to studies that were published several years ago, CSX was considered to be a 
predominantly female disease, with a female to male ratio of 7:3 [27]. However, this finding 
has been put into question by meta-analysis conducted in 2010, which found that the 
percentage of women among CSX patients was 56%, compared to 44% male patients 
[10]. It is therefore not clear whether the label of "female disease" is appropriate or not. 
More generally, it should be noted that among patients presenting with chest pain, for 
whom coronary angiography is performed for suspected myocardial ischaemia originating 
from coronary disease, about 10% of men and 40% of women show non-significant 
coronary artery disease [28,29]. 
The average age of onset of symptoms in patients suffering from CSX is close to 50 years 
of age [30]. 
The heterogeneity of definitions used in the literature to characterize CSX, as well as the 
lack of uniform inclusion and exclusion criteria, demonstrate the challenging nature of 
accurately assessing the incidence and prevalence of CSX in the general population [10]. 
Among patients that undergo coronary angiography, and in whom this examination yields 
normal results, estimated incidences of CSX vary between 3 and 11% [10]. 
2.4 Pathogenesis 
2.4.1 The ischaemic hypothesis 
As already stated previously, myocardial ischaemia probably plays a major role in the 
development of the symptoms and ECG changes typically found in CSX. However, this 
theory remains contentious, not least because the studies which have investigated this 
hypothesis have always been hindered by a small number of study subjects. 
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Some studies used myocardial scintigraphy and assessed coronary flow reserve with 
various techniques, such as PET, argon washout and thermodilution measurements, and 
identified signs of exertion-induced myocardial hypoperfusion in patients with this 
syndrome [15,31]. However, other studies, which used myocardial scintigraphy, 
transoesophageal ultrasound during stress-tests, echo-pacing and SPECT, failed to 
reproduce these results [30,32,33]. Moreover, the presence of left ventricular dysfunction 
in CSX patients was investigated, in studies using echo-pacing, SPECT and the 
assessment of coronary flow reserve by thermodilution measurement, without achieving 
consistent results [32-35]. It was therefore suggested, that given the absence of solid 
evidence of macroscopic ischaemia and left ventricular dysfunction, ischaemia in the 
context of CSX may be limited to the sub-endocardium. This hypothesis was supported by 
a 2002 study which used myocardial magnetic resonance technique to demonstrate that 
patients with CSX have decreased sub-endocardial perfusion, when compared to a control 
group consisting of healthy subjects [36]. Though controversial [37], these findings were 
supported by another myocardial magnetic resonance study, carried out in 2008, that 
showed evidence in favour of a dysfunction of the cardiac microcirculation in patients 
suffering from CSX [38]. Moreover, a study that used phosphorus magnetic resonance, 
carried out in 2000, demonstrated the presence of metabolic indicators, which suggest 
ischaemia, in some patients presenting with chest pain associated with normal coronary 
angiography [39]. A study investigating lipid peroxidation product levels reached a similar 
conclusion (higher levels correlating with myocardial ischaemia) [40, 41]. 
Furthermore, coronary arterioles are the major determinants of coronary resistance [42]. 
However, these arterioles cannot be visualized during coronary angiography [42], which 
hinders effective macroscopic assessment. In addition, it is likely that ischaemia is not 
uniform [43], which further hampers definitive ischaemia diagnosis. 
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In view of the mounting evidence which supports ischaemia as the basis of CSX 
symptoms, it is essential to consider the mechanisms that contribute to ischaemia. At least 
three mechanisms are thought to be involved, namely, endothelial dysfunction, altered 
myocardial adrenergic activity and, possibly, occult coronary artery disease. 
2.4.1.1 Ischaemia from occult coronary artery disease 
The 1995 study by Wiedermann et al. [21], based on intravascular ultrasound (IVUS), 
showed morphological heterogeneity of the coronary arteries in 30 patients apparently 
affected by CSX. Three morphological differences were observed, with a paradoxical 
constrictive vasomotor response to stress that was identified in two of the morphological 
groups. Therefore, although CSX patients have, by definition, coronary arteries that can be 
defined, macroscopically, as “normal”, this study demonstrated that differences exist at 
smaller levels, and that a majority of these patients have epicardial arteries that could be 
defined as “not normal”. However, this study did not address whether these abnormalities 
(atherosclerotic plaques, marked intimal thickening) are sufficient to explain the symptoms 
present in the patients. In 2004 a Sino-German team conducted a study using IVUS and 
intracoronary Doppler measurements, which yielded concurrent findings [44].
Another interesting study, based on coronary computed tomography, conducted by 
Shemesh et al. [45], showed an increased frequency of coronary calcification in patients 
with CSX , when compared to a control group of healthy patients. However, the incidence 
of calcification was still lower in the CSX group, when compared to a group consisting of 
patients with coronary artery disease. However, even in this case the relationship between 
study findings and clinical symptoms could not be firmly established.
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Therefore, though there is evidence of a high prevalence of occult coronary artery disease 
in patients with CSX, these findings have not yet confirmed a clear link between cause and 
effect. 
2.4.1.2 Ischaemia from altered myocardial adrenergic activity 
A 1991 study by Montorsi et al. showed a heterogeneous response to adrenergic 
activation in distal epicardial coronary arteries among CSX patients [46]. In 1997, Lanza et 
al. also highlighted abnormal adrenergic activity in patients with CSX [47], although the 
results did not definitively prove that this difference was closely linked to the pathogenetic 
basis of CSX.
More recently, in 2005 Madaric et al. published another study showing an exaggerated 
myocardial response to adrenergic stimulation [48]. This study included 58 CSX patients 
and 22 control patients, showing that the incidence of a hyperdynamic cardiac response to 
beta-adrenergic stimulation was significantly higher in CSX patients.
These findings confirm the potential contribution of autonomic nervous system 
abnormalities to the pathogenesis of CSX, in the context of an ischaemic origin of the 
syndrome. 
2.4.1.3 Ischaemia from endothelial dysfunction 
Much evidence exists to support the presence of endothelial dysfunction in patients 
affected by CSX, though unanimous and consistent results are lacking. Several studies 
yielded results which could be related to this mechanism. In 1993, a prospective study with 
a control group (19 patients in total) demonstrated that coronary endothelium-dependent 
(acetylcholine stimulation) vasodilation is impaired in subjects with CSX [51]. A second 
prospective study, by the same team, in 1996, with a control group (16 patients), led to 
similar results [52]. In 1995 a correlation between high levels of plasmatic endothelin-1, a 
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potent vasoconstrictor, and the early appearance of chest pain was identified within a 
group of 40 patients affected by CSX. Simultaneously, a higher mean rate of plasmatic 
endothelin-1 was found in the CSX group, when compared to the control group of healthy 
subjects (21 patients in the control group) [53]. Other evidence in favour of coronary 
endothelial dysfunction in patients with CSX was reported in a 1991 study of a group of 23 
patients with typical chest pain, but no macroscopic coronary artery disease. This study 
attempted to establish the coronary reaction to an endothelium-dependent stimulus 
(acetylcholine) and to an endothelium-independent stimulus (dipyridamole), and 
successfully identified a subset of patients (8 out of 23), in which the cause of chest pain 
could be attributed to endothelial dysfunction [54]. In 1999, a prospective study showed a 
link between high concentrations of endothelin and a reduction in coronary blood flow [55]. 
It should be noted however, that recent PET-CT [56-58] and cardiac magnetic resonance 
imaging [59,60] analyses yielded conflicting results.
2.4.2 The “non-ischaemic” hypothesis: altered pain perception
There are several studies that suggest the presence of altered pain perception in patients 
with CSX. Rosen et al. demonstrated that, in patients with CSX, activation at the cortical 
level (right anterior insula) can be observed with PET-CT analysis during dobutamine 
ultrasound stress-testing (test leading to chest pain induction, without myocardial 
dysfunction, in patients with CSX) [61]. This activation is also found in patients who have 
pain related to coronary artery disease, and would therefore be "inadequate" in patients 
CSX. A 2005 study hypothesized that reduced habituation, subsequent to altered central 
processing of painful stimuli, as opposed to increased pain sensitivity, may be a feature of 
CSX [62]. In addition, patients with CSX showed a tendency to present typical chest pain, 
even outside the context of induction of myocardial stress [63], and felt relatively more 
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intense pain when submitted to the same stimuli, when compared to a control group 
[14,16,64-66].  
A combination of various causes can therefore be implicated in the development of CSX 
associated symptoms, including hyperactivity of cardiac nociceptors and exaggerated 
perception of a stimulus, at the cortical level, which normally should be inhibited at the 
sub-cortical level. 
2.5 Diagnosis 
To date, CSX remains a diagnosis of exclusion. There is no specific test to classify a 
patient as having CSX. Patients must have anginal pain upon exertion, transient 
electrocardiographic changes (ST-segment depression) during stress-testing and 
angiographically normal coronary arteries. As stated above, however, there is no 
universally accepted definition of CSX, which hinders the establishment of a standardized 
diagnostic procedure. Therefore CSX is a frustrating syndrome for both physicians and 
patients, particularly in terms of diagnosis, and therapy. 
2.6 Therapy 
Therapy for CSX patients has proven to be complex and challenging, and its effectiveness 
is limited. Conventional therapies include treatment with drugs such as beta-blockers, 
calcium channel blockers, nitrates, nicorandil, and hormone replacement therapy, the use 
of which is based on the fact that a higher prevalence of CSX exists among peri- and post-
menopausal women, though none have yielded satisfactory results. This may be due to 
the absence of specific therapeutic targets, elucidated from reproducible 
pathophysiological studies [67].  
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Beta-blockers 
Any effect of beta-blockers upon the symptoms of CSX may be due to their ability to 
reduce the heart rate and myocardial oxygen demand, while simultaneously increasing 
adrenergic tone. Though beta-blockers are the most efficient therapy currently available for 
the treatment of CSX, their effectiveness is highly variable, ranging from 19 to 75% 
[67-71]. 
Nitrates 
The use of nitrates for controlling CSX symptoms has enjoyed only very limited success, 
with just above 40% of patients presenting an improvement [27]. Also, exercise tolerance 
in nitrate treated CSX patients does not improve, and in some cases may even show some 
deterioration [72-74]. Randomized studies assessing nitrate efficacy in the treatment of 
CSX are scarce. 
Calcium channel blockers 
A four-week therapy with oral nisoldipine has proven effective in controlling symptoms and 
improving exercise tolerance in CSX patients [75]. In contrast, an assessment of the effect 
of orally administered verapamil (compared to propranolol), failed to show any benefit of 
anticalcic therapy [76]. Studies on calcium channel blocker therapy in CSX are limited, and 
mostly evaluate physiological findings, rather than symptom perception data. 
Nicorandil 
Nicorandil was studied in the 1990s, and yielded encouraging results in small groups of 
patients with characteristics that are similar to those observed in CSX [77,78], although 
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there are no studies on the effectiveness of this potassium channel activator on symptoms 
in actual CSX patients. 
Alpha-blockers 
The efficacy of the alpha-blocker drugs doxazosin and clonidine, in the treatment of CSX 
has not been proven to be statistically significant [79,80]. 
Angiotensin converting enzyme inhibitors 
The effect of angiotensin-converting enzyme inhibitor drugs looks promising. A positive 
effect on symptoms and electrocardiographic findings has been reported in some sub-
groups of CSX patients, particularly in patients with pre-hypertension or patients with a 
family history of essential hypertension and documented endothelial dysfunction [68,81]. 
Hormone replacement therapy 
Hormone therapy has been studied ever since a link was proposed between oestrogen 
deficiency and vasomotor instability [82]. This therapeutic approach appears to be 
effective, at least initially, although observational data do not seem to show a marked 
improvement of symptoms. However hormone therapy remains, according to some, the 
most valuable therapy for treating CSX [67,68,83], particularly in female peri- or post-
menopausal patients. Nevertheless, the thromboembolic risk associated with this type of 
therapy must not be underestimated [84-87]. 
HMG-CoA reductase inhibitors 
The positive effects of statins on endothelial function have already been demonstrated in 
the 1990s [88,89]. Specific studies investigating statins and CSX have also been 
undertaken. In a prospective study published in 2003, the positive effects of pravastatin on 
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exercise tolerance, electrocardiographic changes and on endothelial function were 
demonstrated [90]. Similar results were presented in 2004 in a prospective study on 
simvastatin [91]. Statins have also been studied prospectively, in combination with 
angiotensin converting enzyme inhibitors, with encouraging results regarding parameters 
such as flow mediated dilatation and improvement of the quality of life [92]. Statins, alone 
or in combination with other drugs, may prove effective for CSX treatment, by reducing 
oxidative stress  [67]. 
Other pharmacological and non-pharmacological interventions 
Metformin is another drug that has been studied (prospectively, double-blinded, with a 
control group) in a small group of patients presenting characteristics compatible with CSX. 
This study, published in 2006, showed a decrease of anginal symptoms and an 
improvement was observed in exertion electrocardiographic testing results, in the treated 
group when compared to the control group. However, given the limited number of patients 
in the cohort (33 in total), further investigation is required [93].  
Allopurinol, another drug which reduces oxidative stress, was the focus of a study carried 
out between 2008 and 2010, the results of which are pending [94]. 
Even aminophylline was evaluated in the treatment of CSX patients, but its effectiveness 
seems limited [68]. 
Additional drugs with different mechanisms of action, such as ranolazine, could be used in 
the context of treating this rare syndrome [95,96]. 
Other therapeutic interventions are those which merely act as analgesics. Imipramine and 
electrostimulation therapy (TENS, spinal stimulation) yielded encouraging results in some 
patients [67,80]. However, these therapies work to reduce some symptoms, but fail to 
address the pathophysiological basis of CSX. 
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3. PATIENTS AND METHODS 
3.1 Patients 
A total of 37 patients were included in this study. We studied 14 female CSX patients who 
were included in the Italian Registry on Cardiac Syndrome X. One control group consisted 
of 15 female patients with angiographically verified atherosclerotic disease of the coronary 
epicardial vessels. Another control group included 8 healthy female volunteers, with no 
major comorbidities, who were taking no regular medication, and who presented no risk 
factors such as smoking, obesity, hypertension, dyslipidaemia or diabetes mellitus. All 
patients came from the Canton of Ticino, Switzerland. 
3.2 Methods 
3.2.1 Study of endothelial function using a peripheral arterial tonometry device 
There are several clinical tests to assess endothelial function and atherosclerosis. 
However, most of these methods are employed to investigate the advanced stages of 
atherosclerotic disease, and assess anatomical or physiological vascular damage that is 
already evident. 
However, the peripheral arterial tonometry technique is unique. This method quantifies 
endothelium-mediated changes in blood flow, elicited by occlusion of the brachial artery for 
a period of 5 minutes. The occlusion is obtained using a standard blood pressure cuff. 
When the cuff pressure is released, the transient increase in blood flow results in 
endothelium-dependent flow-mediated artery dilatation. Dilatation, which is manifested by 
reactive hyperaemia, is detected by the peripheral arterial tonometry device as an increase 
in the amplitude of the PAT (peripheral arterial tone) signal. For our trial, we used the 
EndoPATTM device, produced by Itamar Medical Ltd, Caesarea, Israel. The pre-occlusion 
 17
to post-occlusion PAT value ratio is calculated by the software of the device, providing an 
RHI index (reactive hyperaemia index), also named the “EndoPAT index”. Software is an 
integral part of the EndoPATTM device, and is used for both acquisition of data during the 
measurements and for analysis, post-acquisition. During data collection, the device allows 
real-time display of measurements. Signals are recorded to allow post-acquisition review 
and to enable automatic analysis of the data. Since the analysis is carried out directly by 
the software, the possibility of intra- or inter-operator variability is excluded. Finally, data 
are automatically exported to an Excel table, which includes several parameters and 
measurements of signal quality, and allows operators to manually calculate other indices 
of interest.
The PAT signal technique is used to non-invasively measure changes in the arterial blood 
flow in the peripheral arterial beds. The PAT signal is measured by recording pulsatile 
arterial volume changes at the fingertips. The EndoPATTM device includes a measuring 
apparatus, connected to a pair of plethysmographic biosensors. These sensors: i) impart a 
sub-diastolic pressure zone at the level of the distal two thirds of the finger, thus avoiding a 
distal venous stasis that could cause a reflex veno-arteriolar vasoconstriction; ii) release 
arterial wall tension, allowing the generation of a greater dynamic range to the PAT signal; 
iii) reduce motion artefacts, by fixing the PAT bio-sensor to the finger. 
 18
Figures 1 and 2: from http://www.precisionhealthdiagnostics.com/Documentation/EndoPOVInternet%20October
%202009.pdf 
All patients were evaluated in the morning after having fasted, and avoided alcohol and 
tobacco for at least 8 hours. Subjects were required to rest for a 10-minute period before 
EndoPATTM measurements were performed. The bio-sensors were then applied to the 
fingertips, bilaterally. Blood flow through the brachial artery was altered by placing a blood 
pressure cuff on the forearm. By inflating the cuff to between 250 and 300 mmHg, 
circulation distal to the cuff was stopped. After 5 minutes the pressure in the cuff was 
released, resulting in the restoration of flow to the brachial artery, and subsequently 
initiating reactive hyperaemia. Signal measurements were recorded at rest and after 
deflating the cuff, allowing further review of these measurements in addition to automatic 
computer analyses. The EndoPAT index is calculated taking into account the average 
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amplitude of signals recorded before cuff inflation and the average amplitude recorded 
during a period of between 90 and 150 seconds after cuff deflation. Test results, including 
multiple parameters, calculated variables and signal quality measurements were then 
exported to an Excel table. EndoPAT indexes <1.67 were deemed as positive for 
endothelial dysfunction (a value which yields a sensitivity of 82% and a specificity of 77%) 
[96,97]. In addition, we subsequently calculated what we call the "EndoPAT index 
according to Bonetti”, which is an index that is determined manually. This value is a ratio 
between data derived from the upper member subjected to alteration of blood flow, at 
different time intervals, and data from the other upper member, at the same modified time 
intervals, without using a baseline value calculated prior to alteration of the blood flow.
Professor Piero Bonetti is the author of several seminal works on endothelial function 
assessment using EndoPATTM. Before commencing our prospective study, we, the 
operators and authors, received appropriate training at Professor Bonetti's reference 
laboratory. In addition, the EndoPATTM device from our research centre was subjected to 
"head to head" comparison testing with the equipment from Professor Bonetti’s reference 
centre. 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4. RESULTS
4.1 Population
Our study population was divided into three groups, a group of “healthy” patients, a group 
of patients with proven coronary artery disease and a group of patients suffering from 
CSX. We carried out data analysis gathered from our three study groups.
Table 1: Distribution of study patients between the three groups (number of patients and mean age 
with range min-max)
Analysis of the results collected during our study shows that the group of healthy patients 
is significantly younger than the other two groups (p=.008).
Group
HEALTHY
number of patients 8
mean age (min-max) 56.75 (51-63)
CORONARY ARTERY DISEASE
number of patients 15
mean age (min-max) 64.33 (57-72)
CSX PATIENTS
number of patients 14
mean age (min-max) 64.86 (43-73)
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Furthermore, the mean height of the group of patients with coronary artery disease was 
significantly lower than that of the other two groups (p=.036), and the BMI of the coronary 
artery disease patients was also significantly higher than the other two groups (p=.044).
However, the weight (kg), did not exhibit statistically significant differences (mean weights 
(kg): 58.8, 67.4, 63.4; p=0.267) between the three groups.
Table 2: Mean height, weight and BMI values in all three groups (mean height, mean weight, mean 
BMI range min-max)
All patients included in the CSX and coronary artery disease groups followed a course of 
drug therapy. In the first group (CSX) 3 patients (21%) were treated with acetylsalicylic 
acid, 2 (14%) with clopidogrel, 8 (57%) with beta-blockers, 4 (29%) with angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers, 8 (57%) with statins, 8 
Group
HEALTHY
mean height (cm) 163.8 (159-169)
mean weight (kg) 58.88 (46-68)
mean BMI (kg/m2) 21.97 (17.97-25.28)
CORONARY ARTERY DISEASE
mean height (cm) 157.4 (140-171)
mean weight (kg) 67.40 (48-95)
mean BMI (kg/m2) 27.31 (18.75-42.22)
CSX PATIENTS
mean height (cm) 161.6 (152-170)
mean weight (kg) 63.43 (42-88)
mean BMI (kg/m2) 24.30 (16.00-30.45)
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(57%) with nitrates, 9 (64%) with calcium channel blockers, 1 (7%) with aminophylline, 7 
(50%) with anxiolytics, 2 (14%) with antidepressants and 3 (21%) were under hormone 
therapy. In the second (CAD) group, 13 patients (87%) were treated with acetylsalicylic 
acid, 6 (40%) with clopidogrel, 11 (73%) with beta-blockers, 9 (60%) with angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers, 15 (100%) with statins, 0 
with nitrates, 3 (20%) with calcium channel blockers, 0 with aminophylline, 2 (13%) with 
anxiolytics and 2 (13%) with antidepressants.
4.2 Results related to endothelial function
EndoPAT index values for the three groups are summarized in Table 3 and in Figure 3. 
According to our results, there were no significant differences between the three study 
groups (p=0.442).
Table 3: Mean EndoPAT index values in the groups (mean EndoPAT index and range min-max)
Group EndoPAT index
HEALTHY
mean EndoPAT index 2.20 (1.46-2.90)
CORONARY ARTERY DISEASE
mean EndoPAT index 2.07 (1.30-3.23)
CSX PATIENTS
mean EndoPAT index 2.39 (1.50-3.82)
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Groups: 
“0” : healthy patients
“1” : CAD patients
“2” : CSX patients
Figure 3: EndoPAT index (95% CI, +/- 1SD)
The same trend was found by analyzing the “EndoPAT index according to Bonetti" data 
(p=0.417).
Table 4: Mean “EndoPAT index values according to Bonetti” in the three groups (mean “EndoPAT 
index according to Bonetti” and range min-max)
Group “EndoPAT index according to Bonetti”
HEALTHY
mean EndoPAT index (Bonetti) 2.04 (1.24-3.59)
CORONARY ARTERY DISEASE
mean EndoPAT index (Bonetti) 1.67 (0.90-3.00)
CSX PATIENTS
mean EndoPAT index (Bonetti) 2.02 (1.14-3.49)
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Groups: 
“0” : healthy patients
“1” : CAD patients
“2” : CSX patients
Figure 4: “EndoPAT indexes according to Bonetti” (95% CI, +/- 1SD)
We also assessed the same values (EndoPAT index and “EndoPAT index according to 
Bonetti”), excluding those patients who were treated with drugs that have a potential effect 
on endothelial function (angiotensin converting enzyme inhibitors, angiotensin receptor 
blockers and calcium channel blockers). Subsequent results showed that the values of 
both the EndoPAT index and the “EndoPAT index according to Bonetti” were found to be 
significantly lower, after exclusion of CSX patients who were treated with calcium channel 
blockers (mean value of 1.96 for the EndoPAT index and of 1.41 for the “EndoPAT index 
according to Bonetti”). However, the same trend was found when patients treated with 
nitrates were excluded from analysis (mean value of 2.14 for the EndoPAT index and of 
1.80 for the “EndoPAT index according to Bonetti”). Furthermore, the average values 
obtained by excluding patients taking statins or angiotensin converting enzyme inhibitors 
are lower than those of the entire cohort, although the difference is smaller. However, at 
this point, the number of patients analysed (5 and 6 patients respectively) was too small to 
obtain statistically meaningful analysis. 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5. DISCUSSION
Data that we have collected and analysed did not allow the determination of statistically 
significant differences between the EndoPAT index and “EndoPAT index according to 
Bonetti” values, obtained for the three groups of patients studied. The reliability of data of 
the EndoPAT index, measured only once in each patient, is proven. These values are 
stable and reproducible in time [99-102] and the methodology was prospectively tested by 
the authors of this study, against that of the reference laboratory.
The absence of significant differences in values of the calculated indexes may be due to 
the small cohort size. CSX is an uncommon disease, and its diagnosis is difficult and 
complex. Furthermore, recognition of this syndrome is not universal, even in the medical 
community, and therefore it may be concluded with certainty that its incidence is 
underestimated, which further complicates patient recruitment for studies [10,27-30]. 
Another confounding factor was the presence, in the coronary artery disease and CSX 
groups, of many patients who were following treatment regimes with drugs that affect 
endothelial function (statins, angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers). It is interesting to observe that when these patients were excluded from 
our analysis, we observed a decrease in the average EndoPAT index values, although the 
groups studied in this case were, as a consequence, extremely small. The decision to 
perform the study without interrupting drug therapy was motivated by the desire to assess 
the potential of this technique for measurement of endothelial function in everyday clinical 
practice. Clearly, an “off medication” approach would be interesting, but is not practical for 
these patients who are highly symptomatic in daily life.
The study groups were significantly heterogeneous with regard to age, height, and BMI. 
The profusion of factors that underlie the development of CSX, along with this 
heterogeneity, are issues which hinder the acquisition of statistically significant results. 
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Another aspect which may have impacted on the results obtained is potentially inherent in 
the methodology used for the measurement of endothelial function, which presents, 
compared to other forms of measurement, such as the flow mediated dilation, greater 
criticality in terms of reproducibility.
The neutral results of our study could, on the other hand, clearly indicate and emphasise 
that the pathophysiology of CSX is complex and multifactorial and not necessarily 
attributable to a single pathophysiological mechanism. This is one of the reasons that 
prompted our group to launch a new study on CSX and on patients suffering from stress 
cardiomyopathy (Takotsubo syndrome) which includes, in addition to the assessment of 
endothelial function, investigation of various other parameters, including those related to 
the autonomic nervous system.
In conclusion, CSX is a rare disease whose incidence is certainly widely underestimated, 
and whose existence is ignored by some part of the medical community. Also, we must not 
underestimate the fact that patients with this syndrome have an increased risk of adverse 
cardiovascular effects [19,20]. The higher incidence of cardiovascular risk factors and 
repeated hospitalizations, caused by angina, lead to a higher number of diagnostic 
procedures performed, with the associated possible iatrogenic effects. Additionally, the 
frustration caused to both patients and physicians cannot be ignored. Patients must live 
with symptoms that are difficult to control, and that significantly alter their quality of life, 
which can prove to be a major source of stress. Clinicians are confronted firstly with 
diagnostic doubt, and secondly with therapies whose effectiveness are often unsatisfactory 
and not without side effects.
It is essential therefore for research to proceed, to simultaneously investigate 
pathophysiology, diagnosis and treatment. These three aspects are clearly closely related. 
If studies on the former are already numerous, they sometimes have lead to conflicting 
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results. Our study sought to test a method that is easy to perform, but potentially useful to 
help to elucidate the pathophysiology of CSX. 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